Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced its operating results for the fourth quarter and year ended December 31, 2013. Revenue and other income for the fourth quarter of 2013 was approximately $399,000, including approximately $53,000 in...
The March 12, 2014, recommendation by a U.S. Food and Drug Administration (FDA) panel to use human papillomavirus (HPV) testing as an alternative to Pap testing for screening of women for cervical cancer has the potential to increase the need for the LuViva® Advanced...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its fourth quarter ended December...
The Secretary General of the International Federation for Cervical Pathology and Colposcopy (IFCPC), Dr. James Bentley, will present results of a new clinical study of the LuViva® Advanced Cervical Scan at the 15th World Congress for Cervical Pathology and Colposcopy,...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), the maker of the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly at the point of care, today announced the appointment of Gene Cartwright, 59, as Chief Executive...
